Launch of Valid Insight provides support for market access
Valid Insight’s launch aims to meet the market access challenges facing new medicines, helping life science research to translate into real-world benefits for patients and society.
Dr Steve Bradshaw, leading a team of key life science advisors and industry experts, has launched Valid Insight, a new market access consultancy created to help drug developers navigate the challenges of market access for new and innovative therapeutics.
Getting new medicines and health technologies to patients who need better treatment is becoming increasingly testing, and payers and health technology assessment bodies are demanding growing levels of evidence to show real-world value.
Valid Insight’s advisors have decades of specialist experience and business knowledge in market access, health economics, outcomes research, and product and health technology launch, pricing and reimbursement. They understand the complexity of the life science landscape and the challenges and hurdles faced by manufacturers, payers, prescribers and patients in demonstrating real-world value.
“We are investing considerable resources in developing our expertise, methods and offerings, including real-world evidence, that help our clients optimize the commercial success of their products,” said Dr Bradshaw, Valid Insight founder and managing director. “I believe that the launch of Valid Insight, and the experts we have on board, will help our clients to build the global landscape of tomorrow’s healthcare environment and deliver better outcomes to patients and society.”
The Valid Insight team will put its expertise to work to provide integrated and strategic research, analysis and value communication solutions to create insight into the market and clinical opportunity, develop evidence, communicate value and build and support centres of excellence through education and training. Its core services are based on its wealth of real in-house expertise and on primary and secondary research, including real-world evidence and research with key opinion leaders and payers.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance